166175-31-1Relevant articles and documents
Syntheses of isotopically labeled 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro- 2-naphthyl)ethenyl]benzoic acid (LGD1069), a potent retinoid X receptor-selective ligand
Zhang,Badea,Enyeart,Berger,Mais,Boehm
, p. 701 - 712 (2007/10/02)
LGD1069, 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl] benzoic acid, is the first retinoid X receptor (RXR) selective retinoid to enter clinical trials for treatment of dermatological diseases and cancer. In order to examine biological properties such as receptor binding, metabolism and bioavailability, [13C]-, [14C]-, and [3H]-labeled LGD1069 is required. Herein, we describe synthetic methods for preparing isotopically labeled homologs of LGD 1069 as well as comparative competition binding data for [6,7-3H]-LGD1069 and [3H]-9-cis retinoic acid with RXR active retinoids. The final radiolabeled products, [6,7-3H]-LGD1069 and 3-[14C]-LGD1069 have specific activities of 56 Ci/mmol and 49 mCi/mmol, respectively. Radiochemical purities are 99.5% for [6,7-3H]-LGD1069 and 99.0% for 3-[14C]-LGD1069. The chemical purity is 99.0% for 3-[13CD3]-LGD1069. Competition binding studies with known retinoids show similar K(d) values when either [6,7-3H]-LGD1069 or [3H]-9-cis retinoic acid is used as the radioligand.
